Factors of energy metabolism in fetal growth restriction
- 作者: Kan N.1, Soldatova E.1, Tyutyunnik V.1, Borisova A.1, Tezikov Y.2, Lipatov I.2, Sadekova A.1, Alekseev A.1, Krasnyi A.1
-
隶属关系:
- Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
- Samara State Medical University, Ministry of Health of Russia
- 期: 编号 5 (2024)
- 页面: 44-52
- 栏目: Original Articles
- URL: https://journals.rcsi.science/0300-9092/article/view/258707
- DOI: https://doi.org/10.18565/aig.2024.9
- ID: 258707
如何引用文章
详细
Objective: This study aimed to was to investigate the blood plasma factors associated with energy metabolism in pregnant women with fetal growth restriction (FGR) and to evaluate their diagnostic performance.
Materials and methods: This cohort study involved 59 pregnant women. The study group (n=30) comprised patients diagnosed with FGR confirmed after childbirth. The control group (n=29) included women with normal pregnancies. The levels of energy metabolism factors (C-peptide, ghrelin, glucose-dependent insulinotropic polypeptide (GlP), glucagon-like peptide-1 (GLP-1), glucagon, insulin, leptin, plasminogen activator inhibitor-1 (PAI-1), resistin, and visfatin) in blood plasma were determined using a multiplex assay (10-plex Bio-Plex Pro Human Diabetes Panel test system).
Results: Analysis of maternal plasma energy metabolism factors revealed significant increases in GLP-1 and PAI-1 levels in the FGR (p=0.003 and p=0.004, respectively). Women with FGR before 37 weeks of gestation showed significant differences in leptin (p=0.05) and PAI-1 (p=0.006) levels compared with those without FGR. After 37 weeks of pregnancy, significant differences were observed in GLP-1 and glucagon levels (p=0.005 and p=0.01, respectively). This study also found that the insulin/GLP-1 ratio was significantly lower in the FGR group than in the control group (p<0.001), suggesting the development of pancreatic cell resistance to GLP-1 and a compensatory increase in its plasma levels in women with FGR. Additionally, a statistically significant direct correlation (rs=0.35, p=0.05) was observed between GLP-1 and PAI-1 (a fibrinolysis inhibitor and a pathogenetically significant factor in FGR). The combination of five factors (GLP-1, glucagon, insulin, leptin, and PAI-1) exhibited excellent diagnostic performance, with an area under the ROC curve of 0.92, a sensitivity of 96%, and a specificity of 81%.
Conclusion: The study results suggest the potential involvement of energy metabolism factors in the development of FGR and highlight prospects for further exploration. Determining the blood plasma levels of GLP-1 and PAI-1 in women with FGR could serve as new non-invasive markers for diagnosing FGR during pregnancy. Furthermore, a combination of factors (GLP-1, glucagon, insulin, leptin, and PAI-1) could identify FGR with high diagnostic accuracy.
作者简介
Natalia Kan
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: kan-med@mail.ru
ORCID iD: 0000-0001-5087-5946
SPIN 代码: 5378-8437
Scopus 作者 ID: 57008835600
Researcher ID: B-2370-2015
Professor, Dr. Med. Sci., Deputy Director of Science
俄罗斯联邦, MoscowEkaterina Soldatova
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
编辑信件的主要联系方式.
Email: katerina.soldatova95@bk.ru
ORCID iD: 0000-0001-6463-3403
PhD student
俄罗斯联邦, MoscowVictor Tyutyunnik
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: tioutiounnik@mail.ru
ORCID iD: 0000-0002-5830-5099
SPIN 代码: 1963-1359
Scopus 作者 ID: 56190621500
Researcher ID: B-2364-2015
Professor, Dr. Med. Sci., Leading Researcher at the Center of Scientific and Clinical Research
俄罗斯联邦, MoscowAnastasia Borisova
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: vvv92@list.ru
PhD student
俄罗斯联邦, MoscowYurii Tezikov
Samara State Medical University, Ministry of Health of Russia
Email: yra.75@inbox.ru
ORCID iD: 0000-0002-8946-501X
SPIN 代码: 2896-6986
Researcher ID: С-6187-2018
Professor, Dr. Med. Sci., Head of the Department of Obstetrics and Gynecology of the Institute of Clinical Medicine
俄罗斯联邦, SamaraIgor Lipatov
Samara State Medical University, Ministry of Health of Russia
Email: i.lipatoff2012@yandex.ru
ORCID iD: 0000-0001-7277-7431
SPIN 代码: 9625-2947
Scopus 作者 ID: 6603787595
Researcher ID: С-5060-2018
Professor, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology of the Institute of Clinical Medicine
俄罗斯联邦, SamaraAlsu Sadekova
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: a_sadekova@oparina4.ru
ORCID iD: 0000-0003-4726-7477
PhD (Bio), Researcher at the Cytology Laboratory
俄罗斯联邦, MoscowAleksey Alekseev
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: a_alekseev@oparina4.ru
ORCID iD: 0000-0002-5347-6884
Junior Researcher at the Cytology Laboratory
俄罗斯联邦, MoscowAleksey Krasnyi
Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: alexred@list.ru
ORCID iD: 0000-0001-7883-2702
PhD (Bio), Head of the Cytology Laboratory
俄罗斯联邦, Moscow参考
- Nardozza L.M., Caetano A.C., Zamarian A.C., Mazzola J.B., Silva C.P., Marçal V.M. et al. Fetal growth restriction: current knowledge. Arch. Gynecol. Obstet. 2017; 295(5): 1061-77. https://dx.doi.org/10.1007/s00404-017-4341-9.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Недостаточный рост плода, требующий предоставления медицинской помощи матери (задержка роста плода). М.; 2022. 76с. [Ministry of Health of the Russian Federation. Clinical guidelines. Insufficient fetal growth requiring maternal medical care (fetal growth restriction). Moscow; 2022. 76p. (in Russian)].
- Hales C.N., Barker D.J. The thrifty phenotype hypothesis. Br. Med. Bull. 2001; 60: 5-20. https://dx.doi.org/10.1093/bmb/60.1.5.
- Oke S.L., Hardy D.B. The role of cellular stress in intrauterine growth restriction and postnatal dysmetabolism. Int. J. Mol. Sci. 2021; 22(13): 6986. https://dx.doi.org/10.3390/ijms22136986.
- Солдатова Е.Е., Кан Н.Е., Тютюнник В.Л., Волочаева М.В. Задержка роста плода с позиции фетального программирования. Акушерство и гинекология. 2022; 8: 5-10. [Soldatova E.E., Kan N.E., Tyutyunnik V.L., Volochaeva M.V. Fetal growth retardation from the perspective of fetal programming. Obstetrics and Gynecology. 2022; (8): 5-10. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.8.5-10.
- Кан Н.Е., Солдатова Е.Е., Тютюнник В.Л., Волочаева М.В., Садекова А.А., Красный А.М. Диагностическая значимость определения экспрессии генов энергетического метаболизма при задержке роста плода. Акушерство и гинекология. 2023; 8: 48-55. [Kan N.E., Soldatova E.E., Tyutyunnik V.L., Volochaeva M.V., Sadekova A.A., Krasnyi A.M. Diagnostic significance of determining the expression of energy metabolism genes in fetal growth retardation. Obstetrics and Gynecology. 2023; (8): 48-55. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.93.
- Рюмина И.И., Байбарина Е.Н., Нароган М.В., Маркелова М.М., Орловская И.В., Зубков В.В., Дегтярев Д.Н. Использование международных стандартов роста для оценки физического развития новорожденных и недоношенных детей. Неонатология: новости, мнения, обучение. 2023; 11(2): 48-52. [Ryumina I.I., Baibarina E.N., Narogan M.V., Markelova M.M., Orlovskaya I.V., Zubkov V.V., Degtyarev D.N. The usage of the international growth standards to assess the physical development of newborn and premature children. Neonatology: News, Opinions, Training. 2023; 11(2): 48-52. (in Russian)]. https://dx.doi.org/10.33029/2308-2402-2023-11-2-48-52.
- de Knegt V.E., Hedley P.L., Kanters J.K., Thagaard I.N., Krebs L., Christiansen M. et al. The role of leptin in fetal growth during pre-eclampsia. Int. J. Mol. Sci. 2021; 22(9): 4569. https://dx.doi.org/10.3390/ijms22094569.
- Masuzaki H., Ogawa Y., Sagawa N., Hosoda K., Matsumoto T., Mise H. et al. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat. Med. 1997; 3(9): 1029-33. https://dx.doi.org/10.1038/nm0997-1029.
- Schanton M., Maymó J.L., Pérez-Pérez A., Sánchez-Margalet V., Varone C.L. Involvement of leptin in the molecular physiology of the placenta. Reproduction. 2018; 155(1): R1-R12. https://dx.doi.org/10.1530/REP-17-0512.
- D'Ippolito S., Tersigni C., Scambia G., Di Simone N. Adipokines, an adipose tissue and placental product with biological functions during pregnancy. Biofactors. 2012; 38(1): 14-23. https://dx.doi.org/10.1002/biof.201.
- Pérez-Pérez A., Toro A., Vilariño-García T., Maymó J., Guadix P., Dueñas J.L. et al. Leptin action in normal and pathological pregnancies. J. Cell. Mol. Med. 2018; 22(2): 716-27. https://dx.doi.org/10.1111/jcmm.13369.
- Khant Aung Z., Grattan D.R., Ladyman S.R. Pregnancy-induced adaptation of central sensitivity to leptin and insulin. Mol. Cell. Endocrinol. 2020; 516: 110933. https://dx.doi.org/10.1016/j.mce.2020.110933.
- Yildiz L., Avci B., Ingeç M. Umbilical cord and maternal blood leptin concentrations in intrauterine growth retardation. Clin. Chem. Lab. Med. 2002; 40(11): 1114-7. https://dx.doi.org/10.1515/CCLM.2002.195.
- Mise H., Yura S., Itoh H., Nuamah M.A., Takemura M., Sagawa N. et al. The relationship between maternal plasma leptin levels and fetal growth restriction. Endocr. J. 2007; 54(6): 945-51. https://dx.doi.org/10.1507/endocrj.k06-225.
- Savvidou M.D., Sotiriadis A., Kaihura C., Nicolaides K.H., Sattar N. Circulating levels of adiponectin and leptin at 23-25 weeks of pregnancy in women with impaired placentation and in those with established fetal growth restriction. Clin. Sci. (Lond). 2008; 115(7): 219-24. https://dx.doi.org/10.1042/CS20070409.
- Müller T.D., Finan B., Bloom S.R., D'Alessio D., Drucker D.J., Flatt P.R. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019; 30: 72-130. https://dx.doi.org/10.1016/j.molmet.2019.09.010.
- Drucker D.J., Habener J.F., Holst J.J. Discovery, characterization, and clinical development of the glucagon-like peptides. J. Clin. Invest. 2017; 127(12): 4217-27. https://dx.doi.org/10.1172/JCI97233.
- Hefetz L., Ben-Haroush Schyr R., Bergel M., Arad Y., Kleiman D., Israeli H. et al. Maternal antagonism of Glp1 reverses the adverse outcomes of sleeve gastrectomy on mouse offspring. JCI Insight. 2022; 7(7): e156424. https://dx.doi.org/10.1172/jci.insight.156424.
- Mehdi S.F., Pusapati S., Anwar M.S., Lohana D., Kumar P., Nandula S.A. et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front. Immunol. 2023; 14: 1148209. https://dx.doi.org/10.3389/fimmu.2023.1148209.
- Ma Z., Paek D., Oh C.K. The cAMP/PKA pathway positively regulates PAI-1 expression in human mast cells. J. Allergy Clin. Immunol. 2009; 123(2): S214. https://dx.doi.org/10.1016/j.jaci.2008.12.818.
- Sheppard B.L., Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth retardation. Semin. Thromb. Hemost. 1999; 25(5): 443-6. https://dx.doi.org/10.1055/s-2007-994947.
- Kaufmann P., Black S., Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol. Reprod. 2003; 69(1): 1-7. https://dx.doi.org/10.1095/biolreprod.102.014977.
- Kam E.P., Gardner L., Loke Y.W., King A. The role of trophoblast in the physiological change in decidual spiral arteries. Hum. Reprod. 1999; 14(8): 2131-8. https://dx.doi.org/10.1093/humrep/14.8.2131.
补充文件
![](/img/style/loading.gif)